As biologics and other complex therapies increasingly move toward self-administration, drug-device combination products require coordinated expertise across development, sterile manufacturing, device assembly, packaging, and commercialization.
In this on-demand resource, Justin Schroder, Global Vice President, Technical Sales, explores the considerations shaping modern combination product development and discusses how an integrated approach can help simplify the journey from clinical development through commercial supply.
What you'll learn
This resource explores:
- The growing role of drug-device combination products in patient-centric drug delivery
- Why integrated development can help simplify clinical-to-commercial transitions
- Considerations for sterile fill-finish, device assembly, packaging, and commercialization
- How platform delivery devices can help accelerate development timelines
- The importance of designing around both product performance and the patient experience
Overview
As more therapies move toward subcutaneous delivery and self-administration, drug developers are balancing increasingly complex technical, operational, and regulatory requirements. Selecting the appropriate delivery platform is only one part of the process. Successful drug-device combination products also depend on coordinated development, sterile manufacturing, device assembly, packaging, and commercial readiness.
In this resource, PCI discusses how an integrated development model supports continuity across the product lifecycle. By bringing pharmaceutical development, sterile fill-finish, clinical supply, device assembly, packaging, and commercialization together within one organization, developers can reduce operational complexity while maintaining momentum from early development through commercial launch.
The presentation also explores the growing use of platform delivery devices, helping developers leverage established technologies to support faster progression into clinical studies and beyond.